Ovarian cancer: relevant therapy, not timing, is paramount.
Morris
Robert T
RT
Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA. rmorris@med.wayne.edu
Monk
Bradley J
BJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy*; D015986:Confounding Factors, Epidemiologic; D004334:Drug Administration Schedule; D055088:Early Detection of Cancer; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D017671:Platinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D017671:Platinum Compounds